It's in the Genes: Health Care ETF Outperforms the S&P 500

The Ark Genomic Revolution ETF (ARC G) focuses on companies in the genomics industry, bridging healthcare and technology. It primarily includes biotech, healthcare services, and pharmaceuticals. The fund holds around 40 companies, such as Illumina and Bristol Myers Squibb, involved in advancements like targeted therapeutics and CRISPR. The genomics industry is valued over $15 billion, with an annual growth forecast of 8.5% until 2025. ARC G has outperformed the S&P 500 since its launch, managing $430 million in assets with a 0.75% expense ratio. It is actively managed and rated positively by Bloomberg Intelligence.

What is the primary focus of the Ark Genomic Revolution ETF?

• Real estate investments

• Genomics industry

• Renewable energy

• Cryptocurrency

Which type of companies make up the majority of the Ark Genomic Revolution ETF?

• Retail companies

• Telecommunication providers

• Biotech firms

• Automobile manufacturers

Which of the following is NOT a company held by the Ark Genomic Revolution ETF?

• Amazon

• Illumina

• MVT

• Teladoc Health

What is the estimated value of the global genomics industry?

• $20 billion

• $5 billion

• $10 billion

• $15 billion

How does the Ark Genomic Revolution ETF compare to the S&P 500 since its launch?

• It has not been compared

• It has outperformed

• It has matched the performance

• It has underperformed